Vigour Pharmaceuticals Ltd. is considering investing in a new  production line for its pain-reliever medicine for individuals who  suffer from cardio vascular diseases. The company has to invest in  equipment which costs $2,500,000 and will be depreciated under the  MACRS system for a 5-year asset class. It is expected to have a scrap  value of $700,000 at the end of the project. Other than the equipment,  the company needs to increase its cash and cash equivalents by  $100,000, increase the level of inventory by $30,000, increase  accounts receivable by $250,000 and increase account payable by  $50,000 at the beginning of the project. Vigour Pharmaceuticals expect  the project to have a life of five years. The company would have to  pay for transportation and installation of the equipment which has an  invoice price of $450,000. The company has already invested $75,000 in Research and Development  and therefore expects a positive impact on the demand for the new  pain-reliever. Expected annual sales for the product in the first  three years are $600,000 and $850,000 in the following two years. The  variable costs of production are projected to be $267,000 per year in  years one to three and $375,000 in years four and five. Fixed overhead  is $180,000 per year over the life of the project. The introduction of the new line of pain reliever will cause a net  decrease of $50,000 in profit contribution due to a decrease in sales  of the other lines of pain relievers produced by the company. By  investing in the new product line Vigour Pharmaceuticals would have  to use a packaging machine which the company already has. It is fully  depreciated and could be sold at the end of the project for $350,000  after-tax in the equipment market. The company’s financial analyst has advised Vigour Pharmaceuticals to  use the weighted average cost of capital as the appropriate discount rate to evaluate the project. The following information about the  company’s sources of financing is provided below: a. The company will contract a new loan in the sum of $2,000,000  that is secured by machinery and the loan has an interest rate  of 6 percent. b. Vigour Pharmaceuticals has also issued 4,000 new bond issues  with an 8 percent coupon, paid semi-annually and matures in 10  years. The bonds were sold at par, and incurred floatation cost  of 2 percent per issue. c. The company’s preferred stock pays an annual dividend of 4.5  percent and is currently selling for $60, and there are 100,000  shares outstanding. d. There are 300,000 shares of common stock outstanding,  and they are currently selling for $21 each. The beta on these  shares is 0.95. Other relevant information is as follows: i. The 20-year Treasury Bond rate is currently 4.5 percent and you  have estimated market-risk premium to be 6.75 percent using the  returns on stocks and Treasury bonds. ii. Vigour Pharmaceuticals has a marginal tax rate of 35 percent. In  the event of a negative taxable income, the tax is computed as  usual and is reported as a negative number, indicating a  reduction in loss after tax. Calculate the initial cash flow of the project

Essentials Of Investments
11th Edition
ISBN:9781260013924
Author:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Chapter1: Investments: Background And Issues
Section: Chapter Questions
Problem 1PS
icon
Related questions
icon
Concept explainers
Topic Video
Question

Vigour Pharmaceuticals Ltd. is considering investing in a new 
production line for its pain-reliever medicine for individuals who 
suffer from cardio vascular diseases. The company has to invest in 
equipment which costs $2,500,000 and will be depreciated under the 
MACRS system for a 5-year asset class. It is expected to have a scrap 
value of $700,000 at the end of the project. Other than the equipment, 
the company needs to increase its cash and cash equivalents by 
$100,000, increase the level of inventory by $30,000, increase 
accounts receivable by $250,000 and increase account payable by 
$50,000 at the beginning of the project. Vigour Pharmaceuticals expect 
the project to have a life of five years. The company would have to 
pay for transportation and installation of the equipment which has an 
invoice price of $450,000.
The company has already invested $75,000 in Research and Development 
and therefore expects a positive impact on the demand for the new 
pain-reliever. Expected annual sales for the product in the first 
three years are $600,000 and $850,000 in the following two years. The 
variable costs of production are projected to be $267,000 per year in 
years one to three and $375,000 in years four and five. Fixed overhead 
is $180,000 per year over the life of the project.
The introduction of the new line of pain reliever will cause a net 
decrease of $50,000 in profit contribution due to a decrease in sales 
of the other lines of pain relievers produced by the company. By 
investing in the new product line Vigour Pharmaceuticals would have 
to use a packaging machine which the company already has. It is fully 
depreciated and could be sold at the end of the project for $350,000 
after-tax in the equipment market.
The company’s financial analyst has advised Vigour Pharmaceuticals to 
use the weighted average cost of capital as the appropriate discount rate to evaluate the project. The following information about the 
company’s sources of financing is provided below:
a. The company will contract a new loan in the sum of $2,000,000 
that is secured by machinery and the loan has an interest rate 
of 6 percent.
b. Vigour Pharmaceuticals has also issued 4,000 new bond issues 
with an 8 percent coupon, paid semi-annually and matures in 10 
years. The bonds were sold at par, and incurred floatation cost 
of 2 percent per issue.
c. The company’s preferred stock pays an annual dividend of 4.5 
percent and is currently selling for $60, and there are 100,000 
shares outstanding.
d. There are 300,000 shares of common stock outstanding, 
and they are currently selling for $21 each. The beta on these 
shares is 0.95.
Other relevant information is as follows:
i. The 20-year Treasury Bond rate is currently 4.5 percent and you 
have estimated market-risk premium to be 6.75 percent using the 
returns on stocks and Treasury bonds.
ii. Vigour Pharmaceuticals has a marginal tax rate of 35 percent. In 
the event of a negative taxable income, the tax is computed as 
usual and is reported as a negative number, indicating a 
reduction in loss after tax.

Calculate the initial cash flow of the project 

Expert Solution
steps

Step by step

Solved in 3 steps

Blurred answer
Knowledge Booster
Capital Budgeting
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.
Similar questions
Recommended textbooks for you
Essentials Of Investments
Essentials Of Investments
Finance
ISBN:
9781260013924
Author:
Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:
Mcgraw-hill Education,
FUNDAMENTALS OF CORPORATE FINANCE
FUNDAMENTALS OF CORPORATE FINANCE
Finance
ISBN:
9781260013962
Author:
BREALEY
Publisher:
RENT MCG
Financial Management: Theory & Practice
Financial Management: Theory & Practice
Finance
ISBN:
9781337909730
Author:
Brigham
Publisher:
Cengage
Foundations Of Finance
Foundations Of Finance
Finance
ISBN:
9780134897264
Author:
KEOWN, Arthur J., Martin, John D., PETTY, J. William
Publisher:
Pearson,
Fundamentals of Financial Management (MindTap Cou…
Fundamentals of Financial Management (MindTap Cou…
Finance
ISBN:
9781337395250
Author:
Eugene F. Brigham, Joel F. Houston
Publisher:
Cengage Learning
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Finance
ISBN:
9780077861759
Author:
Stephen A. Ross Franco Modigliani Professor of Financial Economics Professor, Randolph W Westerfield Robert R. Dockson Deans Chair in Bus. Admin., Jeffrey Jaffe, Bradford D Jordan Professor
Publisher:
McGraw-Hill Education